Pluri Inc

4DX

Company Profile

  • Business description

    Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.

  • Contact

    MATAM Advanced Technology Park
    Building No. 5
    Haifa3508409
    ISR

    T: +972 747108600

    E: [email protected]

    https://www.pluri-biotech.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2026

    Employees

    142

Stocks News & Analysis

stocks

Magellan merger modestly dilutive

Our view on how shareholders should respond to the Magellan merger.
stocks

ASX listed gold miner under pressure due to lower production

Shares have dropped nearly 20% since lowering 2026 volume guidance.
stocks

3 ASX opportunities after earnings season

Uncovering key opportunities following February’s results.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,851.5018.000.20%
CAC 407,974.4938.520.49%
DAX 4023,730.92166.910.71%
Dow JONES (US)46,993.2646.850.10%
FTSE 10010,403.6085.910.83%
HKSE25,825.0843.46-0.17%
NASDAQ22,479.53105.350.47%
Nikkei 22555,165.111,464.722.73%
NZX 50 Index13,315.60133.371.01%
S&P 5006,716.0916.710.25%
S&P/ASX 2008,644.9018.700.22%
SSE Composite Index4,033.6216.29-0.40%

Market Movers